Skip to content

GlobalRPh Renal Dosing Masterv6.8

Clinical interpretation | Version 6.8

Find the difference.
Keep the context.

Search documented disagreements and product cautions across the local library. Compare complete source versions on the drug page before choosing a regimen.

Search source differences

451 notes across 412 drug/product records.

How to interpret these notes

Generic name, brand, source or issueType of differenceAdded in v6.8

Clear filters Export all filtered notes

Search medication names and documented issues only. Do not enter patient information. This directory submits search filters to the server; the within-drug text finder remains a separate local feature.

A difference is not always a contradiction

Compare indication, formulation, route, population, renal method, dialysis conditions and source date. A safety update or source-quality failure is not an alternative dose. These notes are not independent clinical approval, and sources are not ranked or averaged.

451 matching notes. Showing 209-224; page 14 of 29.

renal measure ambiguity

Indigotindisulfonate - BLUDIGO intravenous diagnostic dye

A named renal equation does not repair omitted units

The selected sentence names MDRD but prints mL/min without an indexing denominator.

What to reconcile

Preserve the discrepancy; do not silently convert the measure or infer a below-threshold dose.

1 source identities and dates

GlobalRPh RX List - BLUDIGO

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
BLUDIGO IV dye for ureteral visualization. Not a renal-function diagnostic or a substitute for other dye formulations.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v5.6.

Open / share source review Open drug and compare sources

baseline vs toxicity

Inotersen subcutaneous - TEGSEDI

Proteinuria/eGFR triggers are hold-and-evaluate criteria

The renal triggers require evaluation for kidney injury and glomerulonephritis; they are not a reduced maintenance-dose algorithm.

What to reconcile

Review the complete resumption criteria and separate platelet monitoring. Do not automatically restart when only one laboratory value improves.

1 source identities and dates

GlobalRPh RX List - TEGSEDI

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult subcutaneous inotersen; glomerulonephritis surveillance and treatment-hold criteria.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.3.

Open / share source review Open drug and compare sources

toxicity vs baseline function

Ipilimumab (Yervoy)

Immune nephritis requires toxicity management, not a calculated dose reduction

The new RX section describes withholding or stopping treatment for immune-mediated creatinine toxicity. These CTCAE grades are not the baseline kidney-function categories used in pharmacokinetic assessment.

What to reconcile

Use the oncology toxicity-management protocol for treatment-emergent nephritis, including the combination-treatment rules. Do not reinterpret a baseline no-adjustment statement as permission to continue through significant immune toxicity.

2 source identities and dates

YERVOY - renal function versus immune-mediated renal toxicity

NIH/NLM DailyMed - U.S. product labeling | Source revision: DailyMed updated 2026-08-20.
Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Read this stored source

GlobalRPh RX List - Yervoy

GlobalRPh-hosted RX List | Source revision: May 2025 on retrieved RX page
Adult product-specific renal information; not a complete prescribing regimen.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v3.4.

Open / share source review Open drug and compare sources

evidence limit

Istradefylline - NOURIANZ

NOURIANZ: no-adjustment evidence stops before ESRD

The stated Cockcroft-Gault range does not establish an ESRD or hemodialysis regimen.

What to reconcile

Keep the unstudied population distinct from the supported no-adjustment range.

1 source identities and dates

GlobalRPh RX List - NOURIANZ

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Istradefylline - NOURIANZ; selected source sections, not a full prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.8.

Open / share source review Open drug and compare sources

formulation scope

Itraconazole - ONMEL tablets

Itraconazole: match formulation before applying renal information

These local records keep product-specific renal restrictions or limited-data cautions separate. Shared active ingredient does not establish interchangeable exposure, dosing or route.

What to reconcile

Review the named product, not an adjacent formulation. Historical labeling does not verify current availability.

1 source identities and dates

GlobalRPh RX List - ONMEL

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
ONMEL oral tablets in the selected RX label; not intravenous itraconazole. Current marketing availability not established.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.4.

Open / share source review Open drug and compare sources Itraconazole - related, not interchangeable Itraconazole - SPORANOX injection source - related, not interchangeable Itraconazole - SPORANOX oral solution - related, not interchangeable Itraconazole - TOLSURA capsules - related, not interchangeable

formulation scope

Itraconazole - SPORANOX injection source

Itraconazole: match formulation before applying renal information

These local records keep product-specific renal restrictions or limited-data cautions separate. Shared active ingredient does not establish interchangeable exposure, dosing or route.

What to reconcile

Review the named product, not an adjacent formulation. Historical labeling does not verify current availability.

1 source identities and dates

GlobalRPh RX List - SPORANOX injection

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
SPORANOX intravenous formulation in the retrieved historical RX labeling. Current U.S. marketing availability was not verified.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.4.

Open / share source review Open drug and compare sources Itraconazole - related, not interchangeable Itraconazole - SPORANOX oral solution - related, not interchangeable Itraconazole - TOLSURA capsules - related, not interchangeable Itraconazole - ONMEL tablets - related, not interchangeable

formulation scope

Itraconazole - SPORANOX oral solution

Itraconazole: match formulation before applying renal information

These local records keep product-specific renal restrictions or limited-data cautions separate. Shared active ingredient does not establish interchangeable exposure, dosing or route.

What to reconcile

Review the named product, not an adjacent formulation. Historical labeling does not verify current availability.

1 source identities and dates

GlobalRPh RX List - SPORANOX oral solution

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
SPORANOX oral solution; not the intravenous product or an interchangeable capsule dose.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.4.

Open / share source review Open drug and compare sources Itraconazole - related, not interchangeable Itraconazole - SPORANOX injection source - related, not interchangeable Itraconazole - TOLSURA capsules - related, not interchangeable Itraconazole - ONMEL tablets - related, not interchangeable

formulation scope

Itraconazole - TOLSURA capsules

Itraconazole: match formulation before applying renal information

These local records keep product-specific renal restrictions or limited-data cautions separate. Shared active ingredient does not establish interchangeable exposure, dosing or route.

What to reconcile

Review the named product, not an adjacent formulation. Historical labeling does not verify current availability.

1 source identities and dates

GlobalRPh RX List - TOLSURA

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
TOLSURA oral itraconazole formulation; not an interchangeable conventional capsule or solution product.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.4.

Open / share source review Open drug and compare sources Itraconazole - related, not interchangeable Itraconazole - SPORANOX injection source - related, not interchangeable Itraconazole - SPORANOX oral solution - related, not interchangeable Itraconazole - ONMEL tablets - related, not interchangeable

historical source

Kanamycin injection (KANTREX, historical label)

Historical creatinine-times-nine formula is not a modern dose engine

The 2001 label includes a creatinine-based interval fallback when assays cannot be performed, while preferring serum monitoring and repeated renal assessment.

What to reconcile

Do not automate this historical fallback or imply validation in unstable renal function, modern dialysis or every aminoglycoside regimen. Obtain specialist dosing and concentration interpretation.

1 source identities and dates

GlobalRPh RX List - KANTREX

GlobalRPh-hosted RX List | Source revision: September 17, 2001
Historical IM/IV kanamycin label; serum-level-directed specialist dosing preferred.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.2.

Open / share source review Open drug and compare sources

dose interpretation

Lacosamide (Vimpat)

Reduce the maximum, not automatically every established dose

VIMPAT specifies a reduction in the maximum permitted dose in severe impairment, alongside separate titration and post-HD considerations. It also uses different adult and pediatric renal-function methods.

What to reconcile

Distinguish a maximum-dose ceiling from a mandatory reduction of an already lower dose. Verify adult Cockcroft-Gault versus pediatric Schwartz units, current regimen, dialysis duration and interactions.

1 source identities and dates

GlobalRPh RX List - Vimpat

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
VIMPAT renal maximum and hemodialysis instructions; adult and pediatric renal methods differ.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.0.

Open / share source review Open drug and compare sources

dialysis scope

Lacosamide - MOTPOLY XR

MOTPOLY XR: reduced maximum and dialysis supplement are different decisions

The adult extended-release renal maximum is not a starting dose. The post-dialysis supplement is qualified by the described dialysis session and is not automatic.

What to reconcile

Keep titration, clearance method, interactions and dialysis circumstances with the exact extended-release product.

1 source identities and dates

GlobalRPh RX List - MOTPOLY XR

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Adult MOTPOLY XR extended-release lacosamide capsules; not a pediatric or immediate-release conversion protocol.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.

Open / share source review Open drug and compare sources Lacosamide (Vimpat) - related, not interchangeable

indication scope

Lanreotide - SOMATULINE DEPOT

SOMATULINE DEPOT: acromegaly reduction is not a GEP-NET schedule

The acromegaly dose adjustment and the GEP-NET renal evidence discussion have different scopes. Extended-interval schedules carry additional qualification.

What to reconcile

Confirm indication before applying the renal starting dose or changing the administration interval.

1 source identities and dates

GlobalRPh RX List - SOMATULINE DEPOT

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Lanreotide - SOMATULINE DEPOT; selected renal source sections only, not a complete prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.

Open / share source review Open drug and compare sources

interaction scope

Ledipasvir/sofosbuvir - HARVONI

No HARVONI renal adjustment does not clear the TDF interaction

The product renal statement concerns HARVONI exposure. HCV Guidance separately restricts its combination with tenofovir disoproxil fumarate because of increased tenofovir exposure and renal risk.

What to reconcile

Review the complete antiretroviral regimen, boosters and renal function with the HIV/HCV team. The monitoring paragraph does not cancel the avoidance recommendation; do not generalize TDF instructions to TAF.

2 source identities and dates

GlobalRPh RX List - HARVONI

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Ledipasvir/sofosbuvir oral combination; adult renal statement with pediatric and decompensated-cirrhosis limitations

Read this stored source

AASLD/IDSA HCV guidance - tenofovir interaction and renal risk

AASLD / IDSA HCV Guidance | Source revision: Source revision date not established in selected retrieval.
HIV/HCV coinfection receiving ledipasvir/sofosbuvir with TDF-containing ART

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v3.8.

Open / share source review Open drug and compare sources

indication scope

Lenacapavir - SUNLENCA treatment

SUNLENCA and YEZTUGO: treatment and prevention are separate regimens

A shared active ingredient and renal PK discussion do not make treatment and prevention initiation schedules interchangeable.

What to reconcile

Confirm indication, HIV testing and the complete exact-product regimen. The YEZTUGO supplement here is PK-only.

1 source identities and dates

GlobalRPh RX List - SUNLENCA

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Lenacapavir - SUNLENCA treatment; selected renal source sections only, not a complete prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.

Open / share source review Open drug and compare sources Lenacapavir - YEZTUGO PrEP - related, not interchangeable

indication scope

Lenvatinib (LENVIMA)

LENVIMA: severe-impairment instructions depend on indication

The severe-renal starting doses differ across thyroid, renal and endometrial cancer. The source supplies no corresponding severe-impairment HCC recommendation.

What to reconcile

Match indication and the actual-weight Cockcroft-Gault method; do not substitute another cancer indication's dose.

1 source identities and dates

GlobalRPh RX List - LENVIMA

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Lenvatinib - LENVIMA; selected renal source sections only, not a complete prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.

Open / share source review Open drug and compare sources

formulation scope

Letermovir (PREVYMIS)

PREVYMIS: renal evidence limit versus IV vehicle caution

The adult no-adjustment passage does not extend below its studied clearance boundary. The IV vehicle adds a separate accumulation concern that is not the same as an oral dose adjustment.

What to reconcile

Retain the lower-function evidence limit, exact formulation and kidney monitoring together. Do not convert absence of dialysis evidence into a dialysis regimen.

1 source identities and dates

GlobalRPh RX List - PREVYMIS

GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval.
Letermovir - PREVYMIS; selected renal source sections only, not a complete prescribing monograph.

Read this stored source

Source-specific interpretation; independent clinician adjudication pending. Added: v4.7.

Open / share source review Open drug and compare sources

What is not established by this directory

Only documented issues are searchable here. Absence of a note is not agreement. A label mirror and the original label are not independent corroboration, and a source's retrieval date is not its revision date.

See source and A-Z review status Home / all drugs